Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failure.

Loss of GIMAP6 in mice causes inflammatory vasculopathy and accelerated atherosclerosis without hyperlipidemia, leading to early cardiac ischemia and death.

• Why it matters: Understanding mechanisms beyond hyperlipidemia is crucial because current lipid-focused treatments do not eliminate all ASCVD risk, especially in individuals with genetic variants affecting immune regulation.
• What they did: Researchers studied GIMAP6 deficiency in mice and identified its role in vascular inflammation, mitochondrial ROS production, and lipid-influx pathways, alongside analyzing human GIMAP6 variants linked to ASCVD.
• The result: GIMAP6 loss promotes endothelial failure, foam-cell formation, and inflammation, suggesting it is a key safeguard against lethal ASCVD independently of systemic lipid levels.